首页 > 最新文献

European review for medical and pharmacological sciences最新文献

英文 中文
Potential PDE4A inhibition-mediated neuroprotective effects of psoralidin. 补骨脂素潜在的 PDE4A 抑制介导的神经保护作用
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36913
E Uzunhisarcıklı

Objective: This study aimed to investigate the effect of psoralidin, a natural phenolic coumarin compound, on MK-801-induced neurotoxicity that may cause Alzheimer's disease and to determine the phosphodiesterase (PDE)-related molecular mechanism of action.

Materials and methods: In this study, neurotoxicity was performed using the MK-801 in the HT-22 cell line. The effects of compounds on the proliferation of HT-22 cells were determined by Real-Time Cell Analysis (RTCA). After measuring the total protein concentration, the PDE4A protein level was determined using the Western blot method.

Results: Psoralidin (100, 200, 400 µM) has been shown to have a neuroprotective effect against MK-801-induced neurotoxicity, as indicated by Real-Time Cell Analysis. In HT-22 cells, the half maximal effective concentration (EC50) value of psoralidin was calculated to be 230.4 µM, IC50 value of MK-801 was calculated to be 62.4 µM at 24 hours. It has been determined that psoralidin (200, 400 µM) inhibits PDE4A by using the Western blot method.

Conclusions: This research uncovers that psoralidin has neuroprotective effects in MK801-associated accumulation of the excitatory amino acid glutamate neurodegeneration and Alzheimer's disease.

研究目的本研究旨在探讨天然酚类香豆素化合物补骨脂素对MK-801诱导的可能导致阿尔茨海默病的神经毒性的影响,并确定与磷酸二酯酶(PDE)相关的分子作用机制:本研究使用 MK-801 在 HT-22 细胞系中进行神经毒性实验。化合物对 HT-22 细胞增殖的影响通过实时细胞分析法(RTCA)进行测定。测定总蛋白浓度后,用 Western 印迹法测定 PDE4A 蛋白水平:实时细胞分析显示,补骨脂素(100、200、400 µM)对 MK-801 诱导的神经毒性有保护作用。在 HT-22 细胞中,计算出补骨脂素的半最大有效浓度(EC50)值为 230.4 µM,而 MK-801 在 24 小时内的 IC50 值为 62.4 µM。采用 Western 印迹法测定了补骨脂素(200、400 µM)对 PDE4A 的抑制作用:本研究发现,补骨脂素对与 MK801 相关的兴奋性氨基酸谷氨酸神经变性积累和阿尔茨海默病具有神经保护作用。
{"title":"Potential PDE4A inhibition-mediated neuroprotective effects of psoralidin.","authors":"E Uzunhisarcıklı","doi":"10.26355/eurrev_202411_36913","DOIUrl":"10.26355/eurrev_202411_36913","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effect of psoralidin, a natural phenolic coumarin compound, on MK-801-induced neurotoxicity that may cause Alzheimer's disease and to determine the phosphodiesterase (PDE)-related molecular mechanism of action.</p><p><strong>Materials and methods: </strong>In this study, neurotoxicity was performed using the MK-801 in the HT-22 cell line. The effects of compounds on the proliferation of HT-22 cells were determined by Real-Time Cell Analysis (RTCA). After measuring the total protein concentration, the PDE4A protein level was determined using the Western blot method.</p><p><strong>Results: </strong>Psoralidin (100, 200, 400 µM) has been shown to have a neuroprotective effect against MK-801-induced neurotoxicity, as indicated by Real-Time Cell Analysis. In HT-22 cells, the half maximal effective concentration (EC50) value of psoralidin was calculated to be 230.4 µM, IC50 value of MK-801 was calculated to be 62.4 µM at 24 hours. It has been determined that psoralidin (200, 400 µM) inhibits PDE4A by using the Western blot method.</p><p><strong>Conclusions: </strong>This research uncovers that psoralidin has neuroprotective effects in MK801-associated accumulation of the excitatory amino acid glutamate neurodegeneration and Alzheimer's disease.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4546-4552"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS. 撤稿说明:醛糖还原酶抑制剂依帕司他可通过 ROS 缓解高血糖诱导的心肌细胞凋亡。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36906
X Wang, F Yu, W-Q Zheng

The article "Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS" by X. Wang, F. Yu, W.-Q. Zheng, published in Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl): 294-303-DOI: 10.26355/eurrev_201908_18660-PMID: 31389594 has been retracted by the Editor in Chief. The authors contacted the journal in June 2024, requesting to withdraw the article. Following this request, the journal discovered that the article was commented on PubPeer (link: https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0). The journal started an investigation and asked the authors to provide answers to the concerns raised as well as to send the raw data. Following the journal's requests, the authors neither responded nor provided the raw data. The journal's investigation revealed duplications between panels Blank, HG+1 umol/l, and HG+10 umol/l of Figure 4A. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18660.

文章 "Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS "由X. Wang, F. Yu, W.-Q. Zheng发表在Eur Rev Med Pharmacol Sci 2019; 23 (3 Supp.): Eur Rev Med Pharmacol Sci上。郑,发表于《Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl):294-303-DOI: 10.26355/eurrev_201908_18660-PMID: 31389594 已被主编撤回。作者于 2024 年 6 月联系本刊,要求撤稿。在提出这一请求后,期刊发现该文章在 PubPeer(链接:https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0)上发表了评论。期刊开始调查,并要求作者对提出的问题做出答复,并发送原始数据。在期刊提出要求后,作者既没有回复,也没有提供原始数据。期刊的调查发现,图 4A 的空白、HG+1 umol/l 和 HG+10 umol/l 三组数据存在重复。因此,主编对所提供的结果不信任,决定撤回这篇文章。本文已被撤稿。https://www.europeanreview.org/article/18660。
{"title":"Retraction Note: Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS.","authors":"X Wang, F Yu, W-Q Zheng","doi":"10.26355/eurrev_202411_36906","DOIUrl":"10.26355/eurrev_202411_36906","url":null,"abstract":"<p><p>The article \"Aldose reductase inhibitor Epalrestat alleviates high glucose-induced cardiomyocyte apoptosis via ROS\" by X. Wang, F. Yu, W.-Q. Zheng, published in Eur Rev Med Pharmacol Sci 2019; 23 (3 Suppl): 294-303-DOI: 10.26355/eurrev_201908_18660-PMID: 31389594 has been retracted by the Editor in Chief. The authors contacted the journal in June 2024, requesting to withdraw the article. Following this request, the journal discovered that the article was commented on PubPeer (link: https://pubpeer.com/publications/DE4E22B2B9E506EDC2E650C58152E0). The journal started an investigation and asked the authors to provide answers to the concerns raised as well as to send the raw data. Following the journal's requests, the authors neither responded nor provided the raw data. The journal's investigation revealed duplications between panels Blank, HG+1 umol/l, and HG+10 umol/l of Figure 4A. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18660.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4491"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer. MKNK2作为泛癌潜在预后和免疫生物标志物的研究。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36955
Y-M Zhang, J-K Fan, X-Y Wang, J Liu, T Li, X-S Wang, X-J Yang

Objective: This study aimed to investigate the expression levels of the MKNK2 gene in pan-cancer, its prognostic significance, and its relationship with the tumor immune microenvironment, as well as to assess its potential as an immunological and prognostic biomarker.

Materials and methods: The research utilized data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE), including clinical and mutational information. Bioinformatic tools were employed to analyze the association of MKNK2 with carcinogenesis, including its links to prognosis, immune cell infiltration, tumor immune microenvironment, gene mutation, and the stemness of various tumor cells. A variety of statistical software and analytical tools were applied, including R software, SPSS 27.0, TIMER, CIBERSORT algorithm, and EPIC algorithm.

Results: The study found that MKNK2 is abnormally expressed in pan-cancer and is associated with a poor prognosis. The levels of MKNK2 are highly related to immune cell infiltration and tumor stemness. Notably, in liver hepatocellular carcinoma, glioblastoma multiforme, low-grade gliomas, and acute myeloid leukemia, MKNK2 expression shows a strong correlation with clinical outcomes and immune infiltration. Furthermore, the expression of MKNK2 shows significant correlations with immune cell infiltration, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and stemness scores across various cancers.

Conclusions: The abnormal expression of MKNK2 is associated with tumor progression, immune checkpoint genes, immune cell infiltration, microsatellite instability (MSI), tumor mutational burden (TMB), and stemness in a variety of tumors, especially in glioblastoma multiforme low-grade gliomas (GBMLGG). Therefore, MKNK2 may serve as a potent prognostic physiological marker and provide new avenues for the development of tumor mechanisms and therapeutic strategies targeting MKNK2 to enhance the efficacy of immunotherapy.

目的:本研究旨在探讨MKNK2基因在泛癌中的表达水平、预后意义及其与肿瘤免疫微环境的关系,并评估其作为一种免疫学和预后生物标志物的潜力。材料和方法:研究利用了来自癌症基因组图谱(TCGA)、基因型-组织表达(GTEx)和癌症细胞系百科全书(CCLE)的数据,包括临床和突变信息。利用生物信息学工具分析MKNK2与肿瘤发生的关系,包括其与预后、免疫细胞浸润、肿瘤免疫微环境、基因突变和各种肿瘤细胞的干性的关系。使用多种统计软件和分析工具,包括R软件、SPSS 27.0、TIMER、CIBERSORT算法、EPIC算法。结果:本研究发现,MKNK2在泛癌中异常表达,且与不良预后相关。MKNK2水平与免疫细胞浸润和肿瘤干性高度相关。值得注意的是,在肝细胞癌、多形性胶质母细胞瘤、低级别胶质瘤和急性髓系白血病中,MKNK2的表达与临床结果和免疫浸润有很强的相关性。此外,MKNK2的表达与免疫细胞浸润、免疫检查点、肿瘤突变负担(TMB)、微卫星不稳定性(MSI)和各种癌症的干性评分有显著相关性。结论:MKNK2的异常表达与多种肿瘤的肿瘤进展、免疫检查点基因、免疫细胞浸润、微卫星不稳定性(MSI)、肿瘤突变负担(TMB)和干性有关,尤其是在胶质母细胞瘤多形性低级别胶质瘤(GBMLGG)中。因此,MKNK2可能作为一种有效的预后生理标志物,为开发针对MKNK2的肿瘤机制和治疗策略提供新的途径,以提高免疫治疗的疗效。
{"title":"Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer.","authors":"Y-M Zhang, J-K Fan, X-Y Wang, J Liu, T Li, X-S Wang, X-J Yang","doi":"10.26355/eurrev_202411_36955","DOIUrl":"https://doi.org/10.26355/eurrev_202411_36955","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the expression levels of the MKNK2 gene in pan-cancer, its prognostic significance, and its relationship with the tumor immune microenvironment, as well as to assess its potential as an immunological and prognostic biomarker.</p><p><strong>Materials and methods: </strong>The research utilized data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE), including clinical and mutational information. Bioinformatic tools were employed to analyze the association of MKNK2 with carcinogenesis, including its links to prognosis, immune cell infiltration, tumor immune microenvironment, gene mutation, and the stemness of various tumor cells. A variety of statistical software and analytical tools were applied, including R software, SPSS 27.0, TIMER, CIBERSORT algorithm, and EPIC algorithm.</p><p><strong>Results: </strong>The study found that MKNK2 is abnormally expressed in pan-cancer and is associated with a poor prognosis. The levels of MKNK2 are highly related to immune cell infiltration and tumor stemness. Notably, in liver hepatocellular carcinoma, glioblastoma multiforme, low-grade gliomas, and acute myeloid leukemia, MKNK2 expression shows a strong correlation with clinical outcomes and immune infiltration. Furthermore, the expression of MKNK2 shows significant correlations with immune cell infiltration, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), and stemness scores across various cancers.</p><p><strong>Conclusions: </strong>The abnormal expression of MKNK2 is associated with tumor progression, immune checkpoint genes, immune cell infiltration, microsatellite instability (MSI), tumor mutational burden (TMB), and stemness in a variety of tumors, especially in glioblastoma multiforme low-grade gliomas (GBMLGG). Therefore, MKNK2 may serve as a potent prognostic physiological marker and provide new avenues for the development of tumor mechanisms and therapeutic strategies targeting MKNK2 to enhance the efficacy of immunotherapy.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 22","pages":"4591-4620"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Concern. 表达关切。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36907
No Authors Listed

The Editor in Chief and the Publisher are issuing an expression of concern to alert readers that the following article is under investigation due to a potential ethical breach regarding lack of transparency in the transplantation procedure as outlined in the article published by Rogers W et al (DOI: 10.1136/bmjopen-2018-024473): - Chen J, Zhong L. Clinical significance of serum hepcidin-25 levels in predicting invasive fungal disease in patients after transplantation. Eur Rev Med Pharmacol Sci 2013; 17 (13): 1769-1773-PMID: 23852902. Further updates will be provided once the investigation is completed. The authors have been notified about the ongoing investigation and the publication of this expression of concern.

主编和出版人特此提醒读者,以下文章正在接受调查,原因是Rogers W等人发表的文章(DOI: 10.1136/bmjopen-2018-024473)中所述的移植过程缺乏透明度,可能违反了伦理道德:- Chen J, Zhong L. 血清血红素-25水平在预测移植后患者侵袭性真菌病中的临床意义。Eur Rev Med Pharmacol Sci 2013; 17 (13):1769-1773-PMID: 23852902.一旦调查完成,我们将提供进一步的更新信息。有关正在进行的调查和本关注声明的发布已通知作者。
{"title":"Expression of Concern.","authors":"No Authors Listed","doi":"10.26355/eurrev_202411_36907","DOIUrl":"10.26355/eurrev_202411_36907","url":null,"abstract":"<p><p>The Editor in Chief and the Publisher are issuing an expression of concern to alert readers that the following article is under investigation due to a potential ethical breach regarding lack of transparency in the transplantation procedure as outlined in the article published by Rogers W et al (DOI: 10.1136/bmjopen-2018-024473): - Chen J, Zhong L. Clinical significance of serum hepcidin-25 levels in predicting invasive fungal disease in patients after transplantation. Eur Rev Med Pharmacol Sci 2013; 17 (13): 1769-1773-PMID: 23852902. Further updates will be provided once the investigation is completed. The authors have been notified about the ongoing investigation and the publication of this expression of concern.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4492"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic significance of actionable next-generation sequencing multigene panel in esophageal cancer treatment. 可操作的新一代测序多基因面板在食管癌治疗中的预后意义。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36910
Z Teke, A Bisgin, C Oruc Rencuzogullari, K Eren Erdogan, C K Parsak, S Kalkanli Tas

Objective: Next-generation sequencing (NGS) has been offered as a large-scale and effective genomic analyzing tool. In this research, we seek to examine the possible benefits of an actionable mutation panel in association with clinical and pathological features in the treatment of esophageal cancer.

Patients and methods: In our study, 85 cases whose diagnosis of carcinoma was confirmed histopathologically either by endoscopic biopsy or esophageal surgery between 2010 and 2020 were identified from the hospital database. In formalin-fixed, paraffin-embedded tumor samples, a total of 20 genes of AKT1, ALK, BRAF, DDR, EGFR, ERBB2, ERBB3, ESR1, FGFR1, KIT, KRAS, MAP2K1, MET, NRAS, NTRK, PDGFRA, PIK3CA, PTEN, RICTOR and ROS1 were analyzed via NGS for actionable mutations.

Results: Of 85 cases, 47 patients (55.3%) were men and 38 (44.7%) were women, and the mean age of the patients was 58.01±11.45 years. There were substantial distinctions in the variables of pathogenicity of variant, operation type, stage, and both lymphovascular and perineural invasion (p<0.05). Most of the primary tumors were situated in the lower thoracic esophagus (n=23; 27%). PIK3CA variant was the highest in number among the variant types (n=17) and was detected in 41.2% of the lower thoracic tumors. The increases in mutation numbers of >2 were especially concentrated in the lower thoracic esophageal carcinomas.

Conclusions: The utility of an actionable multigene panel revealed the value of a well-designed NGS workflow in the practical use of clinical outcomes via the prediction of responsiveness to therapeutic agents or indications for novel treatment modalities in addition to the estimation of prognosis.

目的:下一代测序(NGS)是一种大规模、有效的基因组分析工具。在这项研究中,我们试图研究可操作突变面板与临床和病理特征的关联在食管癌治疗中可能带来的益处:在我们的研究中,我们从医院数据库中找出了 2010 年至 2020 年间通过内镜活检或食管手术经组织病理学确诊为癌症的 85 个病例。在福尔马林固定、石蜡包埋的肿瘤样本中,通过 NGS 对 AKT1、ALK、BRAF、DDR、EGFR、ERBB2、ERBB3、ESR1、FGFR1、KIT、KRAS、MAP2K1、MET、NRAS、NTRK、PDGFRA、PIK3CA、PTEN、RICTOR 和 ROS1 共 20 个基因进行了可操作突变分析:85 例患者中,男性 47 例(55.3%),女性 38 例(44.7%),平均年龄(58.01±11.45)岁。在变异的致病性、手术类型、分期、淋巴管和神经周围侵犯(p2尤其集中在下胸段食管癌)等变量方面存在显著差异:可操作的多基因面板揭示了精心设计的 NGS 工作流程在临床结果实际应用中的价值,除了预后评估外,它还能预测对治疗药物的反应性或新型治疗模式的适应症。
{"title":"Prognostic significance of actionable next-generation sequencing multigene panel in esophageal cancer treatment.","authors":"Z Teke, A Bisgin, C Oruc Rencuzogullari, K Eren Erdogan, C K Parsak, S Kalkanli Tas","doi":"10.26355/eurrev_202411_36910","DOIUrl":"10.26355/eurrev_202411_36910","url":null,"abstract":"<p><strong>Objective: </strong>Next-generation sequencing (NGS) has been offered as a large-scale and effective genomic analyzing tool. In this research, we seek to examine the possible benefits of an actionable mutation panel in association with clinical and pathological features in the treatment of esophageal cancer.</p><p><strong>Patients and methods: </strong>In our study, 85 cases whose diagnosis of carcinoma was confirmed histopathologically either by endoscopic biopsy or esophageal surgery between 2010 and 2020 were identified from the hospital database. In formalin-fixed, paraffin-embedded tumor samples, a total of 20 genes of AKT1, ALK, BRAF, DDR, EGFR, ERBB2, ERBB3, ESR1, FGFR1, KIT, KRAS, MAP2K1, MET, NRAS, NTRK, PDGFRA, PIK3CA, PTEN, RICTOR and ROS1 were analyzed via NGS for actionable mutations.</p><p><strong>Results: </strong>Of 85 cases, 47 patients (55.3%) were men and 38 (44.7%) were women, and the mean age of the patients was 58.01±11.45 years. There were substantial distinctions in the variables of pathogenicity of variant, operation type, stage, and both lymphovascular and perineural invasion (p<0.05). Most of the primary tumors were situated in the lower thoracic esophagus (n=23; 27%). PIK3CA variant was the highest in number among the variant types (n=17) and was detected in 41.2% of the lower thoracic tumors. The increases in mutation numbers of >2 were especially concentrated in the lower thoracic esophageal carcinomas.</p><p><strong>Conclusions: </strong>The utility of an actionable multigene panel revealed the value of a well-designed NGS workflow in the practical use of clinical outcomes via the prediction of responsiveness to therapeutic agents or indications for novel treatment modalities in addition to the estimation of prognosis.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4515-4525"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of regimens targeting complete remission in the first-line treatment of acute myeloid leukemia patients. 急性髓性白血病患者一线治疗中以完全缓解为目标的方案比较。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36908
S Yavuz, U Y Malkan

Objective: Standard treatment for adults with acute myeloid leukemia (AML) involves anthracycline and cytarabine, while alternative regimens are necessary for elderly and frail patients. This study aims to compare the effectiveness and safety of various induction regimens in AML patients.

Patients and methods: The retrospective study included 130 adult AML patients treated at a tertiary care center from January 2014 to December 2022. Patients received one of the following induction regimens: anthracycline and cytarabine (n = 82), azacitidine and venetoclax (n = 11), etoposide and cytarabine (n = 22), or reduced-dose anthracycline and cytarabine (n = 15). Data on demographics, clinical characteristics, treatment-related toxicities, and infectious complications were collected. Outcomes included overall survival and remission rates.

Results: The anthracycline and cytarabine regimen demonstrated the highest overall survival rate, although remission rates did not significantly differ among the treatment groups. Patients receiving azacitidine and venetoclax experienced a significantly longer duration of neutropenia. The use of antiviral prophylaxis increased over the study period, reflecting improved management strategies. Infection remained the leading cause of mortality.

Conclusions: Effective management of prolonged neutropenia and infections is crucial for improving patient outcomes. Future research should focus on optimizing prophylactic and infection treatment strategies to further enhance survival in AML.

目的:急性髓性白血病(AML)成人患者的标准治疗方案包括蒽环类和阿糖胞苷,而对于年老体弱的患者则需要采用其他方案。本研究旨在比较各种诱导方案对急性髓性白血病患者的有效性和安全性:这项回顾性研究纳入了2014年1月至2022年12月期间在一家三级医疗中心接受治疗的130名成人急性髓细胞白血病患者。患者接受了以下其中一种诱导方案:蒽环类和阿糖胞苷(82例)、阿扎胞苷和韦尼妥昔单抗(11例)、依托泊苷和阿糖胞苷(22例)或减量蒽环类和阿糖胞苷(15例)。研究人员收集了有关人口统计学、临床特征、治疗相关毒性和感染并发症的数据。结果包括总生存率和缓解率:结果:蒽环类和阿糖胞苷方案的总生存率最高,但各治疗组的缓解率差异不大。接受阿扎胞苷和 Venetoclax 治疗的患者出现中性粒细胞减少的时间明显更长。在研究期间,抗病毒预防措施的使用有所增加,这反映了管理策略的改进。感染仍是导致死亡的主要原因:结论:有效管理长期中性粒细胞减少症和感染对改善患者预后至关重要。未来的研究应侧重于优化预防和感染治疗策略,以进一步提高急性髓细胞白血病患者的生存率。
{"title":"Comparison of regimens targeting complete remission in the first-line treatment of acute myeloid leukemia patients.","authors":"S Yavuz, U Y Malkan","doi":"10.26355/eurrev_202411_36908","DOIUrl":"10.26355/eurrev_202411_36908","url":null,"abstract":"<p><strong>Objective: </strong>Standard treatment for adults with acute myeloid leukemia (AML) involves anthracycline and cytarabine, while alternative regimens are necessary for elderly and frail patients. This study aims to compare the effectiveness and safety of various induction regimens in AML patients.</p><p><strong>Patients and methods: </strong>The retrospective study included 130 adult AML patients treated at a tertiary care center from January 2014 to December 2022. Patients received one of the following induction regimens: anthracycline and cytarabine (n = 82), azacitidine and venetoclax (n = 11), etoposide and cytarabine (n = 22), or reduced-dose anthracycline and cytarabine (n = 15). Data on demographics, clinical characteristics, treatment-related toxicities, and infectious complications were collected. Outcomes included overall survival and remission rates.</p><p><strong>Results: </strong>The anthracycline and cytarabine regimen demonstrated the highest overall survival rate, although remission rates did not significantly differ among the treatment groups. Patients receiving azacitidine and venetoclax experienced a significantly longer duration of neutropenia. The use of antiviral prophylaxis increased over the study period, reflecting improved management strategies. Infection remained the leading cause of mortality.</p><p><strong>Conclusions: </strong>Effective management of prolonged neutropenia and infections is crucial for improving patient outcomes. Future research should focus on optimizing prophylactic and infection treatment strategies to further enhance survival in AML.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4493-4506"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of vitamin D and calcium-sensing receptor gene variants on calcium metabolism in end-stage renal disease: insights from machine learning analysis. 维生素D和钙敏感受体基因变异对终末期肾病钙代谢的影响:来自机器学习分析的见解
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36957
K Sridharan, A Jassim, A M Qader, M M Qader

Objective: End-stage renal disease (ESRD) commonly manifests with disrupted calcium balance, leading to renal osteodystrophy. We posited that variations in the genetic makeup of vitamin D and calcium-sensing receptors, specifically single nucleotide polymorphisms (SNPs), could affect calcium homeostasis. This study aimed to identify the genetic predictors related to vitamin D and calcium-sensing receptors on calcium metabolism using machine learning algorithm analysis in ESRD.

Patients and methods: We conducted a cross-sectional analysis on adults with ESRD. We gathered comprehensive demographic data and medical history. Blood samples were collected to measure SNPs, and a panel of calcium metabolism biomarkers associated with the calcium-sensing receptor and vitamin D receptor. The biomarkers included calcium, phosphate, vitamin D, parathyroid hormone (PTH), sclerostin, procollagen type 1 alpha 1, osteocalcin, and bone-specific alkaline phosphatase. We utilized machine learning algorithms to pinpoint genetic markers predictive of vitamin D deficiency.

Results: We found a notable decrease in serum procollagen type 1 alpha 1 levels among individuals with the CC of rs10190 (related to the calcium-sensing receptor) compared to those with the TT genotype and in those with the TT of rs739837 (pertaining to the vitamin D receptor) compared to the GG genotype. Similarly, the TT genotype of rs10190 was associated with significantly lower serum phosphate levels compared to CC and CT genotypes. Additionally, a lower serum PTH level was noted in individuals with the CT of rs1802757 (calcium-sensing receptor) compared to those with the CC genotype. Our machine learning analysis identified rs2221266 and rs1042636 as the most significant SNPs linked to vitamin D deficiency, demonstrating considerable predictive accuracy.

Conclusions: Our findings indicate that specific single nucleotide polymorphisms in the vitamin D and calcium-sensing receptors significantly influence calcium metabolism biomarkers in ESRD patients. Assessing the clinical implications of these genetic variations is crucial for advancing personalized medicine in renal care.

目的:终末期肾病(ESRD)通常表现为钙平衡破坏,导致肾性骨营养不良。我们假设维生素D和钙敏感受体的基因组成的变化,特别是单核苷酸多态性(snp),可能影响钙的稳态。本研究旨在利用机器学习算法分析ESRD中维生素D和钙敏感受体对钙代谢的相关遗传预测因子。患者和方法:我们对成人ESRD患者进行了横断面分析。我们收集了全面的人口统计数据和病史。收集血液样本来测量snp,以及一组与钙敏感受体和维生素D受体相关的钙代谢生物标志物。生物标志物包括钙、磷酸盐、维生素D、甲状旁腺激素(PTH)、硬化蛋白、前胶原型1 α 1、骨钙素和骨特异性碱性磷酸酶。我们利用机器学习算法来确定预测维生素D缺乏症的遗传标记。结果:我们发现,与TT基因型和GG基因型相比,rs10190基因型(与钙敏感受体有关)和rs739837基因型(与维生素D受体有关)的CC个体血清前胶原型1 α 1水平显著降低。同样,与CC和CT基因型相比,rs10190的TT基因型与血清磷酸盐水平显著降低相关。此外,与CC基因型相比,具有rs1802757(钙敏感受体)CT的个体血清PTH水平较低。我们的机器学习分析发现rs2221266和rs1042636是与维生素D缺乏症相关的最重要的snp,显示出相当高的预测准确性。结论:我们的研究结果表明,维生素D和钙敏感受体的特异性单核苷酸多态性显著影响ESRD患者的钙代谢生物标志物。评估这些遗传变异的临床意义对于推进肾脏护理的个性化医疗至关重要。
{"title":"Influence of vitamin D and calcium-sensing receptor gene variants on calcium metabolism in end-stage renal disease: insights from machine learning analysis.","authors":"K Sridharan, A Jassim, A M Qader, M M Qader","doi":"10.26355/eurrev_202411_36957","DOIUrl":"https://doi.org/10.26355/eurrev_202411_36957","url":null,"abstract":"<p><strong>Objective: </strong>End-stage renal disease (ESRD) commonly manifests with disrupted calcium balance, leading to renal osteodystrophy. We posited that variations in the genetic makeup of vitamin D and calcium-sensing receptors, specifically single nucleotide polymorphisms (SNPs), could affect calcium homeostasis. This study aimed to identify the genetic predictors related to vitamin D and calcium-sensing receptors on calcium metabolism using machine learning algorithm analysis in ESRD.</p><p><strong>Patients and methods: </strong>We conducted a cross-sectional analysis on adults with ESRD. We gathered comprehensive demographic data and medical history. Blood samples were collected to measure SNPs, and a panel of calcium metabolism biomarkers associated with the calcium-sensing receptor and vitamin D receptor. The biomarkers included calcium, phosphate, vitamin D, parathyroid hormone (PTH), sclerostin, procollagen type 1 alpha 1, osteocalcin, and bone-specific alkaline phosphatase. We utilized machine learning algorithms to pinpoint genetic markers predictive of vitamin D deficiency.</p><p><strong>Results: </strong>We found a notable decrease in serum procollagen type 1 alpha 1 levels among individuals with the CC of rs10190 (related to the calcium-sensing receptor) compared to those with the TT genotype and in those with the TT of rs739837 (pertaining to the vitamin D receptor) compared to the GG genotype. Similarly, the TT genotype of rs10190 was associated with significantly lower serum phosphate levels compared to CC and CT genotypes. Additionally, a lower serum PTH level was noted in individuals with the CT of rs1802757 (calcium-sensing receptor) compared to those with the CC genotype. Our machine learning analysis identified rs2221266 and rs1042636 as the most significant SNPs linked to vitamin D deficiency, demonstrating considerable predictive accuracy.</p><p><strong>Conclusions: </strong>Our findings indicate that specific single nucleotide polymorphisms in the vitamin D and calcium-sensing receptors significantly influence calcium metabolism biomarkers in ESRD patients. Assessing the clinical implications of these genetic variations is crucial for advancing personalized medicine in renal care.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 22","pages":"4634-4643"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4. 撤稿说明:MiR-299-3p 通过靶向 TCF4 抑制宫颈癌细胞的增殖和侵袭。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36905
Y Yu, J-D Zhao, H Yang

The article "MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4" by Y. Yu, J.-D. Zhao, H. Yang published in Eur Rev Med Pharmacol Sci 2019; 23 (13): 5621-5627-DOI: 10.26355/eurrev_201907_18296-PMID: 31298314 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/4275612B2FA-7C9A9CD7255B791D3A6), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation revealed data fabrication and several figure manipulations. Specifically, duplications were found within Figures 2C, 2F, 3C, 4A, and 4E. Moreover, Figure 2 (C, D, E), Figure 3C, and Figure 4 (C-D) contained duplications from previously published articles. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18296.

Y. Yu, J.-D. Zhao, H. Yang的文章 "MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4 "发表在《Eur Rev Med Pharmacol Sci 2019; 23 (13): H. Yang》上。Zhao, H. Yang 发表在《Eur Rev Med Pharmacol Sci 2019; 23 (13):5621-5627-DOI: 10.26355/eurrev_201907_18296-PMID: 31298314 已被主编撤回。在PubPeer(链接:https://pubpeer.com/publications/4275612B2FA-7C9A9CD7255B791D3A6)上提出了一些疑虑之后,主编已开始调查,以评估结果的有效性以及可能存在的数据篡改。期刊的调查发现了数据捏造和一些图表篡改。具体来说,在图 2C、2F、3C、4A 和 4E 中发现了重复。此外,图 2(C、D、E)、图 3C 和图 4(C-D)与之前发表的文章重复。本刊已向作者通报了调查情况,但他们一直没有回应,也没有提供研究的原始数据。因此,主编决定撤回这篇文章。这篇文章已被撤回。出版商对此造成的不便深表歉意。https://www.europeanreview.org/article/18296。
{"title":"Retraction Note: MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4.","authors":"Y Yu, J-D Zhao, H Yang","doi":"10.26355/eurrev_202411_36905","DOIUrl":"10.26355/eurrev_202411_36905","url":null,"abstract":"<p><p>The article \"MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4\" by Y. Yu, J.-D. Zhao, H. Yang published in Eur Rev Med Pharmacol Sci 2019; 23 (13): 5621-5627-DOI: 10.26355/eurrev_201907_18296-PMID: 31298314 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/4275612B2FA-7C9A9CD7255B791D3A6), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal's investigation revealed data fabrication and several figure manipulations. Specifically, duplications were found within Figures 2C, 2F, 3C, 4A, and 4E. Moreover, Figure 2 (C, D, E), Figure 3C, and Figure 4 (C-D) contained duplications from previously published articles. The authors have been informed about the journal's investigation but remained unresponsive and have not provided the study's raw data. Consequently, the Editor in Chief decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18296.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4490"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The dead space fraction as a prognostic death indicator in patients with ARDS: a systematic review and meta-analysis. 死亡空间分数作为ARDS患者预后死亡指标:一项系统回顾和荟萃分析。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36953
V Issaris, G P Milas, C G Dragonas, G Poupouzas, N Anagnostopoulos, N Rovina

Objective:   Acute respiratory distress syndrome (ARDS) is a systemic disease with high morbidity and mortality. Dead space fraction (Vd/Vt) represents the volume of air that does not participate in gas exchange and accurately depicts the pathophysiology of ARDS due to ventilation and perfusion mismatch. In this study, we aim to conduct a systematic review and meta-analysis regarding its usefulness for predicting mortality.

Materials and methods: We performed a systematic literature search identifying comparative studies meeting the above criteria from four databases: MEDLINE, clinicaltrials.gov, CENTRAL, and Google Scholar. A statistical meta-analysis was conducted utilizing the "meta" package in R software, with the included studies assessed based on the Newcastle-Ottawa scale.

Results: A total of twelve studies were included and data from over 1,700 patients was collected. Patients with higher levels of Vd/Vt were more likely to not survive with an OR=1.27 [95% CI (1.09, 1.48), I2=93%, p<0.01]. In addition, non-survivors of ARDS had higher mean value levels of Vd/Vt than survivors with an MD=0.07 [95% CI (0.02, 0.11), I2=82%, p<0.01]. Furthermore, a leave-one-out meta-analysis was performed in order to assess the effect of each individual study on the overall outcome, which led to the lowering of heterogeneity to 0.

Conclusions: The Vd/Vt ratio is an accurate index for determining the mortality of ARDS, reflecting the severity of the disease.

目的:急性呼吸窘迫综合征(Acute respiratory distress syndrome, ARDS)是一种高发病率、高死亡率的全身性疾病。死空分数(Vd/Vt)代表不参与气体交换的空气体积,准确描述了通气与灌注失配导致ARDS的病理生理。在这项研究中,我们的目标是对其预测死亡率的有效性进行系统回顾和荟萃分析。材料和方法:我们进行了系统的文献检索,从MEDLINE、clinicaltrials.gov、CENTRAL和谷歌Scholar四个数据库中确定符合上述标准的比较研究。利用R软件中的“meta”包进行统计荟萃分析,并根据纽卡斯尔-渥太华量表对纳入的研究进行评估。结果:共纳入12项研究,收集了1700多名患者的数据。较高Vd/Vt水平的患者更有可能无法生存,OR=1.27 [95% CI (1.09, 1.48), I2=93%],结论:Vd/Vt比值是判断ARDS死亡率的准确指标,反映了疾病的严重程度。
{"title":"The dead space fraction as a prognostic death indicator in patients with ARDS: a systematic review and meta-analysis.","authors":"V Issaris, G P Milas, C G Dragonas, G Poupouzas, N Anagnostopoulos, N Rovina","doi":"10.26355/eurrev_202411_36953","DOIUrl":"10.26355/eurrev_202411_36953","url":null,"abstract":"<p><strong>Objective: </strong>  Acute respiratory distress syndrome (ARDS) is a systemic disease with high morbidity and mortality. Dead space fraction (Vd/Vt) represents the volume of air that does not participate in gas exchange and accurately depicts the pathophysiology of ARDS due to ventilation and perfusion mismatch. In this study, we aim to conduct a systematic review and meta-analysis regarding its usefulness for predicting mortality.</p><p><strong>Materials and methods: </strong>We performed a systematic literature search identifying comparative studies meeting the above criteria from four databases: MEDLINE, clinicaltrials.gov, CENTRAL, and Google Scholar. A statistical meta-analysis was conducted utilizing the \"meta\" package in R software, with the included studies assessed based on the Newcastle-Ottawa scale.</p><p><strong>Results: </strong>A total of twelve studies were included and data from over 1,700 patients was collected. Patients with higher levels of Vd/Vt were more likely to not survive with an OR=1.27 [95% CI (1.09, 1.48), I2=93%, p<0.01]. In addition, non-survivors of ARDS had higher mean value levels of Vd/Vt than survivors with an MD=0.07 [95% CI (0.02, 0.11), I2=82%, p<0.01]. Furthermore, a leave-one-out meta-analysis was performed in order to assess the effect of each individual study on the overall outcome, which led to the lowering of heterogeneity to 0.</p><p><strong>Conclusions: </strong>The Vd/Vt ratio is an accurate index for determining the mortality of ARDS, reflecting the severity of the disease.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 22","pages":"4561-4575"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of adropin level and insulin resistance in non-alcoholic fatty liver patients: a meta-analysis of studies. 评估非酒精性脂肪肝患者的阿托品水平和胰岛素抵抗:研究荟萃分析。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-11-01 DOI: 10.26355/eurrev_202411_36909
F Alzoughool, R Abdelqader, S Abumweis, A Al-Bashaireh, Y Aljawarneh, M Alzghool, L Alanagreh

Objective: The recently discovered protein adropin is a highly conserved polypeptide that plays critical functions in energy homeostasis, metabolic processes, fat metabolism, and insulin resistance. On the other hand, non-alcoholic fatty liver disease (NAFLD) is a medical condition that causes the buildup of fat in the liver cells in individuals who consume little or no alcohol. The frequency of NAFLD is rising globally, and it is frequently linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Therefore, this study evaluates the association between adropin levels and insulin resistance in individuals with and without NAFLD.

Materials and methods: Data from Scopus, Science Direct, and PubMed were searched between January 1, 2012, and February 18, 2024, using precise terms and stated criteria. Comprehensive Meta-Analysis V. 2 (Biostat, Englewood, NJ, USA) was used for data analysis, and Random-effect models were used to estimate the pooled mean differences with 95% CIs of adropin level, insulin level, and homeostatic model assessment for insulin resistance (HOMA-IR) associated with the exposures of interest.

Results: Our results revealed that adropin blood levels are significantly reduced in NAFLD patients compared to control individuals. The mean difference in adropin blood levels was 2.391 ng/ml with a 95% CI of 1.127 to 3.656 with I2 99.6. on the other hand, insulin resistance was significantly higher in NAFLD compared to controls (MD: -1.668, 95% CI: -2.333 to -1.002, I2=86%).

Conclusions: Our findings reveal that adropin levels are significantly greater in healthy controls than in NAFLD patients, suggesting that adropin may have a preventative effect on NAFLD. This meta-analysis highlights how closely adropin and insulin resistance interact in non-alcoholic fatty liver disease. Also, it may open the door to new diagnostic tools and therapeutic modalities.

目的:最近发现的蛋白阿德蛋白是一种高度保守的多肽,在能量平衡、新陈代谢过程、脂肪代谢和胰岛素抵抗中发挥着重要功能。另一方面,非酒精性脂肪肝(NAFLD)是一种医学病症,会导致很少饮酒或不饮酒的人的肝细胞内脂肪堆积。非酒精性脂肪肝的发病率在全球呈上升趋势,而且经常与肥胖、胰岛素抵抗、2 型糖尿病和代谢综合征有关。因此,本研究评估了非酒精性脂肪肝患者和非酒精性脂肪肝患者体内阿托品水平与胰岛素抵抗之间的关系:在 2012 年 1 月 1 日至 2024 年 2 月 18 日期间,使用精确的术语和规定的标准从 Scopus、Science Direct 和 PubMed 中检索数据。采用随机效应模型估算与相关暴露相关的阿托品水平、胰岛素水平和胰岛素抵抗稳态模型评估(HOMA-IR)的集合均值差异及 95% CI:我们的研究结果表明,与对照组相比,非酒精性脂肪肝患者的腺肌肽血药浓度明显降低。另一方面,与对照组相比,非酒精性脂肪肝患者的胰岛素抵抗显著升高(MD:-1.668,95% CI:-2.333 至-1.002,I2=86%):我们的研究结果表明,非酒精性脂肪肝患者的阿托品水平明显高于健康对照组,这表明阿托品可能对非酒精性脂肪肝有预防作用。这项荟萃分析凸显了非酒精性脂肪肝中阿托品与胰岛素抵抗之间的密切相互作用。此外,它还为新的诊断工具和治疗方法打开了大门。
{"title":"Evaluation of adropin level and insulin resistance in non-alcoholic fatty liver patients: a meta-analysis of studies.","authors":"F Alzoughool, R Abdelqader, S Abumweis, A Al-Bashaireh, Y Aljawarneh, M Alzghool, L Alanagreh","doi":"10.26355/eurrev_202411_36909","DOIUrl":"10.26355/eurrev_202411_36909","url":null,"abstract":"<p><strong>Objective: </strong>The recently discovered protein adropin is a highly conserved polypeptide that plays critical functions in energy homeostasis, metabolic processes, fat metabolism, and insulin resistance. On the other hand, non-alcoholic fatty liver disease (NAFLD) is a medical condition that causes the buildup of fat in the liver cells in individuals who consume little or no alcohol. The frequency of NAFLD is rising globally, and it is frequently linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Therefore, this study evaluates the association between adropin levels and insulin resistance in individuals with and without NAFLD.</p><p><strong>Materials and methods: </strong>Data from Scopus, Science Direct, and PubMed were searched between January 1, 2012, and February 18, 2024, using precise terms and stated criteria. Comprehensive Meta-Analysis V. 2 (Biostat, Englewood, NJ, USA) was used for data analysis, and Random-effect models were used to estimate the pooled mean differences with 95% CIs of adropin level, insulin level, and homeostatic model assessment for insulin resistance (HOMA-IR) associated with the exposures of interest.</p><p><strong>Results: </strong>Our results revealed that adropin blood levels are significantly reduced in NAFLD patients compared to control individuals. The mean difference in adropin blood levels was 2.391 ng/ml with a 95% CI of 1.127 to 3.656 with I2 99.6. on the other hand, insulin resistance was significantly higher in NAFLD compared to controls (MD: -1.668, 95% CI: -2.333 to -1.002, I2=86%).</p><p><strong>Conclusions: </strong>Our findings reveal that adropin levels are significantly greater in healthy controls than in NAFLD patients, suggesting that adropin may have a preventative effect on NAFLD. This meta-analysis highlights how closely adropin and insulin resistance interact in non-alcoholic fatty liver disease. Also, it may open the door to new diagnostic tools and therapeutic modalities.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 21","pages":"4507-4514"},"PeriodicalIF":3.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European review for medical and pharmacological sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1